Kanion Pharmaceutical: Wholly-owned subsidiary's drug receives approval for additional indications

Kanion Pharmaceutical announced that its wholly-owned subsidiary Jiangsu Zhongxin Pharmaceutical Co., Ltd. recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration regarding the new indication for ZX2021 injection for the treatment of metabolic dysfunction-related fatty liver disease

A-share weight loss drug concept stocks continued to weaken in the afternoon, Menovo hit the limit down, Medicilon and Kanion Pharmaceutical fell over 7%, SDKX and HISOAR had the largest declines

The three major A-share indices rose collectively, with a significant increase in the biopharmaceutical sector. CPO continues to squeeze shorts, while Hong Kong stocks fluctuated and fell, tech stocks retreated, and government bonds and commodities declined

The A-share innovative drug sector saw a short-term surge, with Kanion Pharmaceutical hitting the daily limit, and Gan & Lee, NuoSiLanDe, Xintian Pharma, and others rising significantly. The CPO concept continues to squeeze shorts, with Zhongji Xuchuang rising over 4%, and its total market value surpassing 300 billion yuan for the first time; Cambridge Technology has achieved three consecutive limit-ups in five days, and Dekeli has risen over 10%

Kanion Pharmaceutical: Clinical trial for Jianpi Shugan Guben Granules approved

According to the Zhitong Finance APP, Kanion Pharmaceutical announced that the company has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the Jianpi Shugan Guben Granules. The relevant drug is Jianpi Shugan Guben Granules, indicated for diarrhea-type irritable bowel syndrome with liver stagnation and spleen deficiency

The traditional Chinese medicine concept continues to strengthen, with Layn hitting the daily limit, and companies such as Zhongsheng Pharmaceutical, Kanion Pharmaceutical, JINGXIN, Zhendong Pharmacy, CONBA, and Chase Sun also rising